Malignant mesothelioma 2008

Purpose of review Mesothelioma is an aggressive malignancy of the pleura with poor survival. There will be approximately 3000 cases of mesothelioma in the United States annually. Multimodality treatment including neoadjuvant chemotherapy in selected individuals followed by extrapleural pneumonectomy and radiation has been studied in recent trials for its effects on disease free and overall survival This review provides a general overview of malignant mesothelioma with a summary of the most significant articles from within the past year as well as from the past. Recent findings Areas of recent interest include the evaluation of osteopontin and mesothelin as new tumor markers for mesothelioma. New phase III trials have been performed to evaluate the use of combined chemotherapy regimens. Summary Malignant mesothelioma is a very difficult malignancy to treat. Patients with the disease usually have an occupational asbestos exposure, and in some, viral exposure with SV40. There have been many historical treatments including combinations of local control with surgery and radiation as well as attempts to prevent systemic failure with chemotherapy. Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.

[1]  Platelet-derived growth factor in human malignancy. , 1992, BioFactors.

[2]  N. Sardesai,et al.  MESOMARK: a potential test for malignant pleural mesothelioma. , 2007, Clinical chemistry.

[3]  L. Johansson,et al.  Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. , 1996, The European respiratory journal.

[4]  K. O'Byrne,et al.  The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  R. Ginsberg,et al.  Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Iwano,et al.  Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  H. Pass,et al.  Integration of multimodality approaches in the management of malignant pleural mesothelioma. , 2004, Clinical lung cancer.

[8]  D. Waller,et al.  Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  J. Marsella,et al.  Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. , 1997, Environmental health perspectives.

[10]  Silverman Bj.  Platelet-derived growth factor in human malignancy. , 1992 .

[11]  P. Okunieff,et al.  Schedule-Dependent Pulsed Paclitaxel Radiosensitization for Thoracic Malignancy , 2001, American journal of clinical oncology.

[12]  P. Jänne,et al.  Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Cheng,et al.  Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two‐hit mechanism of NF2 inactivation , 1999, Genes, chromosomes & cancer.

[14]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  J. Herndon,et al.  Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.

[16]  K. Forster,et al.  Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. , 2007, The Annals of thoracic surgery.

[17]  H. Pass,et al.  Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Nowak.  CT, RECIST, and malignant pleural mesothelioma. , 2005, Lung cancer.

[19]  H. Pass,et al.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. , 2008, The Annals of thoracic surgery.

[20]  V. Rusch,et al.  Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Morris,et al.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.

[22]  K. Uematsu,et al.  p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53 , 2001 .

[23]  P. Pairolero,et al.  Malignant pleural mesothelioma: surgical management in 285 patients. , 2008, The Annals of thoracic surgery.

[24]  A. Gazdar,et al.  SV40 and human tumours: myth, association or causality? , 2002, Nature Reviews Cancer.

[25]  C. Cicala,et al.  SV40 induces mesotheliomas in hamsters. , 1993, The American journal of pathology.

[26]  D. Waller,et al.  Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[27]  S. Larson,et al.  Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. , 2003, The Journal of thoracic and cardiovascular surgery.

[28]  C. A. van der Merwe,et al.  Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Nackaerts,et al.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  K R Abrams,et al.  Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems , 2000, Thorax.

[31]  K. Uematsu,et al.  Advances in Brief p 14 ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p 53 , 2001 .

[32]  I. Pastan,et al.  Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma , 1992, The American journal of surgical pathology.

[33]  T. Treasure,et al.  The MARS trial: mesothelioma and radical surgery. , 2005, Interactive cardiovascular and thoracic surgery.

[34]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[35]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[36]  H. Pass,et al.  Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters , 2006, Proceedings of the National Academy of Sciences.

[37]  F. Barlesi,et al.  Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma , 2007, Cancer.

[38]  W. Richards,et al.  Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. , 2004, The Journal of thoracic and cardiovascular surgery.

[39]  E. Yorke,et al.  A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  A. Chella,et al.  A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[41]  D. Waller,et al.  The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[42]  S. Hahn,et al.  Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  E. Butchart.  Contemporary management of malignant pleural mesothelioma. , 1999, The oncologist.

[44]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[45]  D. Sugarbaker,et al.  Diffuse malignant mesothelioma of the pleural space and its management. , 2002, Oncology.

[46]  K. Rosenzweig,et al.  Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  D. Waller,et al.  The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. , 2006, The Journal of thoracic and cardiovascular surgery.

[48]  K. Rosenzweig,et al.  Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. , 2005, International journal of radiation oncology, biology, physics.

[49]  V. Rusch,et al.  A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Rusch,et al.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. , 1999, The Annals of thoracic surgery.

[51]  S. Larson,et al.  Positron emission tomography predicts survival in malignant pleural mesothelioma. , 2006, The Journal of thoracic and cardiovascular surgery.

[52]  G. Hillerdal,et al.  Eighth International Mesothelioma Interest Group , 2007, Oncogene.

[53]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[54]  S. Steinberg,et al.  Surgically debulked malignant pleural mesothelioma: Results and prognostic factors , 1996, Annals of Surgical Oncology.

[55]  R. Salgado,et al.  Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients , 1999, British Journal of Cancer.

[56]  Cindy B. Yeoh,et al.  Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  L. Broemeling,et al.  Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. , 2005, The Journal of thoracic and cardiovascular surgery.

[58]  R. Cerfolio,et al.  Endoscopic ultrasound‐guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma , 2008, Diagnostic cytopathology.

[59]  S. Steinberg,et al.  Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma , 1997, Annals of Surgical Oncology.

[60]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[61]  Zhandong Liu,et al.  Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.

[62]  K. Forster,et al.  Radiotherapy for mesothelioma. , 2005, Hematology/oncology clinics of North America.

[63]  R. Davies,et al.  Catheter-tract metastases associated with chronic indwelling pleural catheters. , 2007, Chest.

[64]  R. Stupp,et al.  Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  D. Sterman,et al.  Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. , 2001, Chest.

[66]  K. Rosenzweig,et al.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.

[67]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Gilligan,et al.  The role of radiotherapy in the treatment of malignant pleural mesothelioma. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[69]  F. McCormick,et al.  A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. , 2003, Anticancer research.